Renal Medicine 2 Early recognition and prevention of chronic kidney disease

被引:466
作者
James, Matthew T. [3 ,4 ]
Hemmelgarn, Brenda R. [3 ,4 ]
Tonelli, Marcello [1 ,2 ]
机构
[1] Univ Alberta, Dept Med, Div Nephrol & Immunol, Edmonton, AB T6G 2G3, Canada
[2] Univ Alberta, Ctr Hlth Econ, Edmonton, AB T6G 2G3, Canada
[3] Univ Calgary, Dept Med, Calgary, AB, Canada
[4] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada
关键词
GLOMERULAR-FILTRATION-RATE; CONVERTING-ENZYME-INHIBITION; URINARY ALBUMIN EXCRETION; EVALUATION PROGRAM KEEP; BLOOD-PRESSURE CONTROL; ALL-CAUSE MORTALITY; SERUM CYSTATIN-C; CARDIOVASCULAR-DISEASE; DIABETES-MELLITUS; RISK-FACTORS;
D O I
10.1016/S0140-6736(09)62004-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic kidney disease is a common disorder and its prevalence is increasing worldwide. Early diagnosis on the basis of presence of proteinuria or reduced estimated glomerular filtration rate could permit early intervention to reduce the risks of cardiovascular events, kidney failure, and death that are associated with chronic kidney disease. In developed countries, screening for the disorder is most efficient when targeted at high-risk groups including elderly people and those with concomitant illness (such as diabetes, hypertension, or cardiovascular disease) or a family history of chronic kidney disease, although the role of screening in developing countries is not yet clear. Effective strategies are available to slow the progression of chronic kidney disease and reduce cardiovascular risk. Treatment of high blood pressure is recommended for all individuals with, or at risk of, chronic kidney disease. Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers is preferred for patients with diabetic chronic kidney disease or those with the proteinuric non-diabetic disorder. Glycaemic control can help prevent the onset of early stages of chronic kidney disease in individuals with diabetes. Use of statins and aspirin is beneficial for most patients with chronic kidney disease who are at high cardiovascular risk, although research is needed to ascertain how to best prevent cardiovascular disease in this cohort. Models of care that facilitate delivery of the many complex aspects of treatment simultaneously could enhance management, although effects on clinical outcomes need further assessment. Novel clinical methods to better identify patients at risk of progression to later stages of chronic kidney disease, including kidney failure, are needed to target management to high-risk subgroups.
引用
收藏
页码:1296 / 1309
页数:14
相关论文
共 135 条
[1]   Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis - A randomized controlled trial [J].
Agodoa, LY ;
Appel, L ;
Bakris, GL ;
Beck, G ;
Bourgoignie, J ;
Briggs, JP ;
Charleston, J ;
Cheek, D ;
Cleveland, W ;
Douglas, JG ;
Douglas, M ;
Dowie, D ;
Faulkner, M ;
Gabriel, A ;
Gassman, J ;
Greene, T ;
Hall, Y ;
Hebert, L ;
Hiremath, L ;
Jamerson, K ;
Johnson, CJ ;
Kopple, J ;
Kusek, J ;
Lash, J ;
Lea, J ;
Lewis, JB ;
Lipkowitz, M ;
Massry, S ;
Middleton, J ;
Miller, ER ;
Norris, K ;
O'Connor, D ;
Ojo, A ;
Phillips, RA ;
Pogue, V ;
Rahman, M ;
Randall, OS ;
Rostand, S ;
Schulman, G ;
Smith, W ;
Thornley-Brown, D ;
Tisher, CC ;
Toto, RD ;
Wright, JT ;
Xu, SC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (21) :2719-2728
[2]   Detection of chronic kidney disease with laboratory reporting of estimated glomerular filtration rate and an educational program [J].
Akbari, A ;
Swedko, PJ ;
Clark, HD ;
Hogg, W ;
Lemelin, J ;
Magner, P ;
Moore, L ;
Ooi, D .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (16) :1788-1792
[3]   UK consensus conference on early chronic kidney disease - 6 and 7 February 2007 [J].
Archibald, G. ;
Bartlett, W. ;
Brown, A. ;
Christie, B. ;
Elliott, A. ;
Griffith, K. ;
Pound, S. ;
Rappaport, I. ;
Robertson, D. ;
Semple, Y. ;
Slane, P. ;
Whitworth, C. ;
Williams, B. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (09) :2455-2457
[4]   The changing patterns of chronic kidney disease: The need to develop strategies for prevention relevant to different regions and countries [J].
Atkins, RC .
KIDNEY INTERNATIONAL, 2005, 68 :S83-S85
[5]   First united kingdom heart and renal protection (UK-HARP-1) study: Biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease [J].
Baigent, C ;
Landray, M ;
Leaper, C ;
Altmann, P ;
Armitage, J ;
Baxter, A ;
Cairns, HS ;
Collins, R ;
Foley, RN ;
Frighi, V ;
Kourellias, K ;
Ratcliffe, PJ ;
Rogerson, M ;
Scoble, JE ;
Tomson, CRV ;
Warwick, G ;
Wheeler, DC .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (03) :473-484
[6]   SCreening for Occult REnal Disease (SCORED) - A simple prediction model for chronic kidney disease [J].
Bang, Heejung ;
Vupputuri, Suma ;
Shoham, David A. ;
Klemmer, Philip J. ;
Falk, Ronald J. ;
Mazumdar, Madhu ;
Gipson, Debbie ;
Colindres, Romulo E. ;
Kshirsagar, Abhijit V. .
ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (04) :374-381
[7]   Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy [J].
Barnett, AH ;
Bain, SC ;
Bouter, P ;
Karlberg, B ;
Madsbad, S ;
Jervell, J ;
Mustonen, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (19) :1952-1961
[8]   Chronic kidney disease in the developing world [J].
Barsoum, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :997-999
[9]   Staging of chronic kidney disease: Time for a course correction [J].
Bauer, Carolyn ;
Melamed, Michal L. ;
Hostetter, Thomas H. .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 19 (05) :844-846
[10]   Effect of Candesartan on Microalbuminuria and Albumin Excretion Rate in Diabetes Three Randomized Trials [J].
Bilous, Rudy ;
Chaturvedi, Nish ;
Sjolie, Anne Katrin ;
Fuller, John ;
Klein, Ronald ;
Orchard, Trevor ;
Porta, Massimo ;
Parving, Hans-Henrik .
ANNALS OF INTERNAL MEDICINE, 2009, 151 (01) :11-U27